OTC Markets OTCQB - Delayed Quote USD
(ONNVF)
1.5000
0.0000
(0.00%)
At close: March 26 at 4:00:00 PM EDT
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Thomas O'Shaughnessy | Chief Executive Officer | -- | -- | 1977 |
| Mr. Nico Mah | CFO & Corporate Secretary | -- | -- | 1996 |
| Dr. Fadia Saad M.B.A., Ph.D. | Consultant | -- | -- | 1964 |
| Dr. Frederick West | Technology Transfer Advisor | -- | -- | -- |
ONNVF
1309 - 7th Street SW
Calgary, AB T2R 1A5
Canada
- Full Time Employees:
- 1
Description
Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3'-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.
Corporate Governance
ONNVF’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available